Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594155 | 1.00 | CA1 (0.53) | CA1CA2STSMAPTEPHX2 | |
| SCHEMBL31114566 | 0.86 | EPHX2 (0.55) | CA1CA2STSMAPTEPHX2 | |
| Hydrochloric Acid SCHEMBL32677541 | 0.84 | EPHX2 (0.54) | CA1CA2STSMAPTEPHX2 | |
| SCHEMBL26933468 | 0.83 | LMNA (0.57) | CA1CA2STSMAPTEPHX2 | |
| SCHEMBL26933474 | 0.83 | LMNA (0.57) | CA1CA2STSMAPTEPHX2 | |
| SCHEMBL16147114 | 0.83 | EPHX2 (0.61) | CA1CA2STSMAPTEPHX2 | |
| SCHEMBL20232018 | 0.80 | GAA (0.43) | CA1CA2MAPTCA12CA7 | |
| SCHEMBL21876839 | 0.80 | GAA (0.43) | CA1CA2MAPTCA12CA7 | |
| SCHEMBL12875463 | 0.80 | SLC6A4 (0.56) | CA1CA2MAPTEPHX2FAAH | |
| SCHEMBL8339652 | 0.80 | PARP10 (0.60) | CA1CA2MAPTEPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-118059104-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-115175901-B | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4077309-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115175901-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021127443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | CA1 691/4885CA2 355/4885STS 294/4885 |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CA1 1904/4885CA2 3012/4885STS 525/4885 |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CA1 1904/4885CA2 3012/4885STS 525/4885 |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | CA1 1904/4885CA2 3012/4885STS 525/4885 |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | CA1 1904/4885CA2 3012/4885STS 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.